Two Sigma Investments LP acquired a new stake in Cyclacel (NASDAQ:CYCC) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 70,310 shares of the biotechnology company’s stock, valued at approximately $122,000.

Separately, Citadel Advisors LLC purchased a new position in Cyclacel in the fourth quarter valued at about $108,000. 6.53% of the stock is currently owned by institutional investors and hedge funds.

Shares of Cyclacel stock opened at $1.47 on Friday. Cyclacel has a 12-month low of $1.28 and a 12-month high of $6.15. The stock has a market capitalization of $17.52, a price-to-earnings ratio of -0.42 and a beta of 3.63.

CYCC has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Cyclacel from a “buy” rating to a “hold” rating in a report on Friday, April 6th. ValuEngine raised shares of Cyclacel from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Cyclacel in a report on Thursday, March 29th.

COPYRIGHT VIOLATION WARNING: “Two Sigma Investments LP Acquires Shares of 70,310 Cyclacel (CYCC)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2018/04/22/two-sigma-investments-lp-acquires-shares-of-70310-cyclacel-cycc.html.

About Cyclacel

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Want to see what other hedge funds are holding CYCC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cyclacel (NASDAQ:CYCC).

Institutional Ownership by Quarter for Cyclacel (NASDAQ:CYCC)

Receive News & Ratings for Cyclacel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel and related companies with MarketBeat.com's FREE daily email newsletter.